For crystal-impurity systems with
similar structures and molecular
weights, the impurity has a strong tendency to incorporate into the
crystal lattice, making it difficult to obtain high purity with a
single crystallization or even multiple crystallizations. In such
cases, complexation of the impurity with an additive can be used to
sterically prevent impurity incorporation in the host lattice. A nanofiltration
membrane can be used to preferentially reject the higher molecular
weight impurity complex in solution, while allowing the lower molecular
weight API to permeate through. This permeate stream can be concentrated
and recycled to operate the crystallization in a continuous mode with
the aim of enhancing both yield and crystal purity simultaneously.
In the present work, this strategy was applied to the continuous cooling
crystallization of two systems in a mixed-suspension mixed-product
removal (MSMPR) crystallizer from their solutions in 50:50 (by volume)
water–ethanol mixed solvent. The first system consists of benzamide
with 3-nitrobenzoic acid added as an impurity, while the second one
is the active pharmaceutical ingredient (API) ketoprofen containing
two impurities, ibuprofen and α,4-dimethylphenylacetic
acid. A working strategy for selecting the complexing agent and nanofiltration
membrane was established. For both systems, the membrane-coupled continuous
mode with recycle and complexation was found to have a better performance
in terms of higher crystallization yield and lower impurity incorporation
in crystals compared to both the batch process as well as the continuous
process without recycle.
Functionalized nanoporous silica can induce crystallization from undersaturated solutions due to the combined effects of antisolvent functionalization and confinement.
In
API-impurity systems consisting of structural isomers, the impurity
has a strong affinity to incorporate into the host crystal owing to
their identical molecular weight and similar structure. Conventional
successive recrystallization turns out to be an unattractive purification
strategy in such cases, since it can improve crystal purity only at
the cost of yield. As an alternative, selective complexation of the
impurity can sterically prevent its incorporation into the host lattice
by increasing the apparent molecular weight and dimensions of the
impurity. The increase in size of the impurity post complexation can
be further exploited using a nanofiltration membrane to preferentially
reject the complex in solution, while allowing the smaller molecules
of uncrystallized API to permeate through. The crystallization yield
can be enhanced by concentrating the permeate stream and recycling
it back to the crystallizer. Thus, complexation-assisted nanofiltration
recycle presents a strategy to improve both yield and crystal purity
simultaneously in a continuous mode. In the present work, the application
of this strategy is described for the continuous cooling crystallization
of two isomeric systems in a mixed-suspension mixed-product removal
(MSMPR) crystallizer. The first system consists of 4-nitrophenol with
3-nitrophenol as an added impurity in an aqueous solvent, while the
second one consists of the active pharmaceutical ingredient (API)
acetaminophen with its isomer 3-acetamidophenol added as an impurity
in a mixed solvent of 50:50 ethanol and water by volume. A working
strategy for selecting the complexing agent and nanofiltration membrane
is discussed. For both systems, the complexation-assisted continuous
mode with nanofiltration recycle performed better than both the batch
process as well as the unrecycled MSMPR process in terms of higher
crystallization yield and lower impurity incorporation in crystals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.